Wrist Device, Medical Software Web Claims Draw Warning Letters
This article was originally published in The Gray Sheet
Executive Summary
Carpal Kinetics' Wristrac for treatment of Carpal Tunnel Syndrome requires a 510(k) because the device differs from other nonpowered orthopedic traction devices, FDA informs the firm in a warning letter released Oct. 26
You may also be interested in...
Tecan U.S. Compliance Difficulties Dampen North American Q3 Sales
Tecan is taking steps to bolster its regulatory processes, following compliance problems that emerged during an FDA inspection of the firm's Durham, N.C. facility
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.